Success Metrics

Clinical Success Rate

87.7%

Based on 64 completed trials

Completion Rate

88%(64/73)

Active Trials

1(1%)

Results Posted

72%(46 trials)

Terminated

9(10%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

Ph phase_3

29%

Ph not_applicable

Ph phase_4

34%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution80 total trials

Phase 1Safety & dosage

17(21.3%)

Phase 2Efficacy & side effects

3(3.8%)

Phase 3Large-scale testing

25(31.3%)

Phase 4Post-market surveillance

29(36.3%)

N/ANon-phased studies

6(7.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.2%

64 of 76 finished

Non-Completion Rate

15.8%

12 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(64)

Terminated(12)

Other(7)

Detailed Status

Completed64

Terminated9

unknown7

Withdrawn3

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.7%

Most Advanced

Phase 4

Trials by Phase

Phase 117 (21.3%)

Phase 23 (3.8%)

Phase 325 (31.3%)

Phase 429 (36.3%)

N/A6 (7.5%)

Trials by Status

not_yet_recruiting22%

unknown78%

withdrawn33%

recruiting11%

completed6474%

terminated910%

Recent Activity

1 active trials

Showing 5 of 86

completedphase_4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

NCT06851962

not_yet_recruitingnot_applicable

Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

NCT07786571

completednot_applicable

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

NCT05313529

terminatedphase_1

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

NCT03281369

terminatedphase_1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

NCT03337698

View all 86 trials

Clinical Trials (86)

Showing 20 of 86 trialsScroll for more

NCT06851962Phase 4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Completed

NCT07786571Not Applicable

Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

Not Yet Recruiting

NCT05313529Not Applicable

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Completed

NCT03281369Phase 1

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Terminated

NCT03337698Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Terminated

NCT06095492Not Applicable

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Recruiting

NCT01734785Phase 3

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Completed

NCT03429543Phase 3

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Completed

NCT03642184Phase 4

Efficacy and Safety of Empagliflozin in NODAT